10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2024-08-14 (Q2 2024) | Holdings: 95 | Value: $7.8B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| INCY - Incyte Corporation | Reduce 15% $(329.8M) | 23.81% | $1.9B | +5.29% | +22.79% | ||
| BGNE - BeiGene, Ltd. | 19.27% | $1.5B | +29.25% | -0.41% | |||
| ACAD - ACADIA Pharmaceuticals Inc. | 8.90% | $696.8M | +39.52% | +8.47% | |||
| MDGL - Madrigal Pharmaceuticals, Inc. | 7.07% | $553.2M | +10.88% | +16.24% | |||
| RVMD - Revolution Medicines, Inc. | 3.75% | $293.8M | -9.59% | +26.50% | |||
| RYTM - Rhythm Pharmaceuticals, Inc. | 3.36% | $262.7M | +30.85% | +19.97% | |||
| INSM - Insmed Incorporated | Add 943% ($216.6M) | 3.06% | $239.6M | -7.53% | -12.09% | ||
| BCYC - Bicycle Therapeutics plc | Add 90% ($90.2M) | 2.43% | $190.3M | -63.53% | -3.33% | ||
| SMMT - Summit Therapeutics Inc. | New Purchase | 2.31% | $181.1M | +59.08% | +59.91% | ||
| KYMR - Kymera Therapeutics, Inc. | 2.29% | $179.0M | -32.56% | -4.53% | |||
| EWTX - Edgewise Therapeutics, Inc. | 1.34% | $105.2M | -18.54% | +79.35% | |||
| ALKS - Alkermes plc | New Purchase | 1.29% | $100.8M | +14.13% | +5.11% | ||
| N/A - Insmed Incorporated | New Purchase | 1.16% | $90.4M | ||||
| REPL - Replimune Group, Inc. | Add 5% ($4.5M) | 1.16% | $90.4M | -10.20% | +8.00% | ||
| DNLI - Denali Therapeutics Inc. | 1.11% | $86.6M | -42.76% | +8.30% | |||
| ABCL - AbCellera Biologics Inc. | 1.04% | $81.5M | -24.06% | -0.38% | |||
| NRIX - Nurix Therapeutics, Inc. | 1.04% | $81.0M | -52.61% | +2.18% | |||
| IMTX - Immatics N.V. | 0.96% | $74.9M | -54.90% | -31.63% | |||
| TRDA - Entrada Therapeutics, Inc. | 0.89% | $69.3M | -53.23% | +9.85% | |||
| RARE - Ultragenyx Pharmaceutical Inc. | 0.77% | $60.3M | -35.19% | -14.78% | |||
| STOK - Stoke Therapeutics, Inc. | Add 30% ($13.5M) | 0.75% | $59.0M | -33.98% | -16.75% | ||
| N/A - Insmed Incorporated | New Purchase | 0.72% | $56.2M | ||||
| KNSA - Kiniksa Pharmaceuticals International, plc | New Purchase | 0.67% | $52.6M | +5.27% | -18.08% | ||
| IMCR - Immunocore Holdings plc | 0.66% | $51.4M | -1.74% | -15.19% | |||
| ARGX - argenx SE | Reduce 26% $(16.9M) | 0.61% | $48.1M | +8.73% | +7.01% | ||
| KOD - Kodiak Sciences Inc. | 0.52% | $40.7M | +25.93% | +104.81% | |||
| XENE - Xenon Pharmaceuticals Inc. | 0.50% | $38.7M | -26.38% | +1.63% | |||
| PRLD - Prelude Therapeutics Inc. | 0.49% | $38.6M | -83.32% | -80.41% | |||
| IDYA - IDEAYA Biosciences, Inc. | 0.48% | $37.3M | -47.60% | -29.82% | |||
| CERS - Cerus Corporation | 0.44% | $34.3M | -40.65% | -19.63% | |||
| SERA - Sera Prognostics, Inc. | 0.41% | $32.2M | -77.29% | -10.63% | |||
| KRYS - Krystal Biotech, Inc. | 0.40% | $31.2M | -34.43% | -11.11% | |||
| CELC - Celcuity Inc. | Add 21% ($5.3M) | 0.39% | $30.7M | -38.45% | -26.69% | ||
| ROIV - Roivant Sciences Ltd. | Reduce 62% $(48.8M) | 0.38% | $29.6M | -4.43% | -2.61% | ||
| IGMS - IGM Biosciences, Inc. | 0.36% | $28.1M | -86.52% | +0.53% | |||
| CERE - Cerevel Therapeutics Holdings, Inc. | Reduce 57% $(37.5M) | 0.36% | $28.0M | ||||
| AKRO - Akero Therapeutics, Inc. | Reduce 60% $(37.9M) | 0.33% | $25.7M | +102.74% | +14.70% | ||
| DYN - Dyne Therapeutics, Inc. | New Purchase | 0.30% | $23.7M | -73.43% | -36.93% | ||
| ALMS - Alumis Inc. | New Purchase | 0.27% | $20.8M | -72.74% | -31.07% | ||
| GLUE - Monte Rosa Therapeutics, Inc. | 0.23% | $18.4M | -10.49% | +65.74% | |||
| MRUS - Merus N.V. | New Purchase | 0.23% | $17.8M | +9.40% | -9.11% | ||
| NGNE - Neurogene Inc. | 0.21% | $16.6M | -50.47% | +0.51% | |||
| TCRX - TScan Therapeutics, Inc. | 0.21% | $16.3M | -75.47% | -24.36% | |||
| SANA - Sana Biotechnology, Inc. | 0.17% | $13.0M | -55.98% | -50.91% | |||
| IMVT - Immunovant, Inc. | Add 9% ($1.0M) | 0.16% | $12.3M | -51.60% | -13.20% | ||
| XNCR - Xencor, Inc. | 0.13% | $10.3M | -50.37% | +43.11% | |||
| NMRA - Neumora Therapeutics, Inc. | New Purchase | 0.13% | $10.2M | -93.73% | -5.16% | ||
| FATE - Fate Therapeutics, Inc. | Add 65% ($3.9M) | 0.13% | $9.8M | -64.72% | -41.11% | ||
| TSVT - 2seventy bio, Inc. | 0.12% | $9.6M | -22.30% | ||||
| BMEA - Biomea Fusion, Inc. | 0.12% | $9.5M | -74.19% | +17.03% | |||
| ADAP - Adaptimmune Therapeutics plc | Reduce 100% | 0.00% | $0.00 | ||||
| AVTE - Aerovate Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| BCRX - BioCryst Pharmaceuticals, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| CLDX - Celldex Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| DBVT - DBV Technologies S.A. | Reduce 100% | 0.00% | $0.00 | ||||
| RLAY - Relay Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| TSHA - Taysha Gene Therapies, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| VERV - Verve Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| KNSA - Kiniksa Pharmaceuticals, Ltd. | Reduce 100% | 0.00% | $0.00 | ||||